Professor Christopher Fegan

2022

• Burley, T. A. et al. 2022. Elucidation of focal adhesion kinase as a modulator of migration and invasion and as a potential therapeutic target in chronic lymphocytic leukemia. Cancers 14(7), article number: 1600. (10.3390/cancers14071600)

2021

• Alsagaby, S. A. et al. 2021. Proteomics-based identification of cancer-associated proteins in chronic lymphocytic leukaemia. Electronic Journal of Biotechnology 52, pp. 1-12. (10.1016/j.ejbt.2021.04.006)
• Kennedy, E. et al. 2021. TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target. Blood 137(22), pp. 3064-3078. (10.1182/blood.2020005964)
• Lewis, T. et al. 2021. Novel pyrrolobenzodiazepine benzofused hybrid molecules inhibit NF-κB activity and synergise with bortezomib and ibrutinib in hematological cancers. Haematologica 106(4), pp. 958-967. (10.3324/haematol.2019.238584)
• Moat, S. J. et al. 2021. Development of a high throughput SARS-CoV-2 antibody testing pathway using dried blood spot specimens. Annals of Clinical Biochemistry 58(2) (10.1177/0004563220981106)

2020

• Zelek, W. M. et al. 2020. Complement inhibition with the C5 blocker LFG316 in severe COVID-19. American Journal of Respiratory and Critical Care Medicine 202(9), pp. 1304-1308. (10.1164/rccm.202007-2778LE)
• O'Donnell, V. B. et al. 2020. Potential role of oral rinses targeting the viral lipid envelope in SARS-CoV-2 infection. Function 1(1), article number: zqaa002. (10.1093/function/zqaa002)
• Rule, S. A. et al. 2020. Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059) [Letter]. Leukemia 34, pp. 1458-1461. (10.1038/s41375-019-0658-7)
• Elston, L. et al. 2020. Increased frequency of CD4+PD-1+HLA-DR+ T cells is associated with disease progression in CLL. British Journal of Haematology 188(6), pp. 872-880. (10.1111/bjh.16260)
• Pepper, C., Norris, K. and Fegan, C. 2020. Clinical utility of telomere length measurements in cancer. Current Opinion in Genetics and Development 60, pp. 107-111. (10.1016/j.gde.2020.02.012)

2019

• Cohen, J. A. et al. 2019. A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia. Haematologica 104(11), article number: 228171. (10.3324/haematol.2019.228171)
• Norris, K., Hillmen, P., Rawstron, A., Hills, R., Baird, D. M., Fegan, C. D. and Pepper, C. 2019. Telomere length predicts for outcome to FCR chemotherapy in CLL. Leukemia 33, pp. 1953-1963. (10.1038/s41375-019-0389-9)
• Escudero, L., Cleal, K., Ashelford, K., Fegan, C., Pepper, C., Liddiard, K. and Baird, D. M. 2019. Telomere fusions associate with coding sequence and copy number alterations in CLL. Leukemia 33, pp. 2093-2097. (10.1038/s41375-019-0423-y)

2018

• Went, M. et al. 2018. Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology. Blood Cancer Journal 9, article number: 1. (10.1038/s41408-018-0162-8)

2017

• Hyatt, S. et al. 2017. Telomere length is a critical determinant for survival in multiple myeloma. British Journal of Haematology 178(1), pp. 94-98. (10.1111/bjh.14643)
• Williams, J. et al. 2017. Telomere length is an independent prognostic marker in MDS but not in de novo AML. British Journal of Haematology 178(2), pp. 240-249.
• Law, P. J. et al. 2017. Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. Nature Communications 8, article number: 14175. (10.1038/ncomms14175)
• Law, P. J. et al. 2017. Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci. Scientific Reports 7, article number: 41071. (10.1038/srep41071)
• Pepper, C. J., Tu, H., Morrill, P., Garcia-Rates, S., Fegan, C. and Greenfield, S. 2017. Tumor cell migration is inhibited by a novel therapeutic strategy antagonizing the alpha-7 receptor. Oncotarget (10.18632/oncotarget.14545)

2016

• Pasikowska, M. et al. 2016. Phenotype and immune function of lymph node and peripheral blood CLL cells are linked to transendothelial migration. Blood 128(4), pp. 563-573. (10.1182/blood-2016-01-683128)
• Parry, H. . M. et al. 2016. Cytomegalovirus infection does not impact on survival or time to first treatment in patients with Chronic Lymphocytic Leukaemia. American Journal of Hematology 91(8), pp. 776-781. (10.1002/ajh.24403)

2015

• Nichols, E., Jones, R., Watson, R., Pepper, C. J., Fegan, C. D. and Marchbank, K. 2015. A CD21 low phenotype, with no evidence of autoantibodies to complement proteins, is consistent with a poor prognosis in CLL. Oncotarget 6(32), pp. 32669-32680. (10.18632/oncotarget.5404)
• Pepper, C. et al. 2015. Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition. Leukemia 29, pp. 744-747. (10.1038/leu.2014.308)
• Sava, G. P. et al. 2015. Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia risk. Leukemia 29, pp. 748-751. (10.1038/leu.2014.311)
• Reid, R., Redman, J. E., Rizkallah, P., Fegan, C. D., Pepper, C. J. and Man, S. T. 2015. CD8+ T-cell recognition of a synthetic epitope formed by t-butyl modification. Immunology 144(3), pp. 495-505. (10.1111/imm.12398)
• Fegan, C. D. and Pepper, C. J. 2015. Understanding cancer cell survival is key to patient survival. The Lancet Oncology 16(2), pp. 122-124. (10.1016/S1470-2045(15)70003-3)

2014

• Lin, T. T. et al. 2014. Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease. British Journal of Haematology 167(2), pp. 214-223. (10.1111/bjh.13023)
• Walsby, E. et al. 2014. Development and characterization of a physiologically relevant model of lymphocyte migration in chronic lymphocytic leukemia. Blood 123(23), pp. 3607-3617. (10.1182/blood-2013-12-544569)
• Bulian, P. et al. 2014. CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. Journal of Clinical Oncology 32(9), pp. 897-904. (10.1200/JCO.2013.50.8515)
• Pepper, C. J., Baird, D. M. and Fegan, C. D. 2014. Telomere analysis to predict chronic lymphocytic leukemia outcome: a STELA test to change clinical practice?. Expert Review of Hematology 7(6), pp. 701-703. (10.1586/17474086.2014.969705)
• Alsagaby, S. A. et al. 2014. Proteomics-based strategies to identify proteins relevant to chronic lymphocytic leukemia. Journal of Proteome Research 13(11), pp. 5051-5062. (10.1021/pr5002803)

2013

• Wong, R. F., Pepper, C. J., Brennan, P., Nagorsen, D., Man, S. T. and Fegan, C. D. 2013. Blinatumomab induces autologous T cell killing of chronic lymphocytic leukemia cells. Haematologica 98(12), pp. 1930-1938. (10.3324/haematol.2012.082248)
• Groves, M. et al. 2013. p53 and cell cycle independent dysregulation of autophagy in chronic lymphocytic leukaemia. British Journal of Cancer 109(9), pp. 2434-2444. (10.1038/bjc.2013.601)
• Chubb, D. et al. 2013. Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk. Nature Genetics 45(10), pp. 1221-1225. (10.1038/ng.2733)

2012

• Walsby, E. J., Pearce, L., Burnett, A. K., Fegan, C. D. and Pepper, C. J. 2012. The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells. Oncotarget 3(5), pp. 525-534.

2011

• Watkins, C. L., Sayers, E. J., Allender, C. J., Barrow, D. A., Fegan, C. D., Brennan, P. and Jones, A. T. 2011. Co-operative membrane disruption between cell-penetrating peptide and cargo: implications for the therapeutic use of the Bcl-2 converter peptide D-NuBCP-9-r8. Molecular Therapy 19(12), pp. 2124-2132. (10.1038/mt.2011.175)

2010

• Pourgheysari, B., Bruton, R., Parry, H., Billingham, L., Fegan, C. D., Murray, J. and Moss, P. 2010. The number of cytomegalovirus-specific CD4+ T cells is markedly expanded in patients with B-cell chronic lymphocytic leukemia and determines the total CD4+ T-cell repertoire. Blood 116(16), pp. 2968-2974. (10.1182/blood-2009-12-257147)
• Crowther-Swanepoel, D. et al. 2010. Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nature Genetics 42(2), pp. 132-136. (10.1038/ng.510)

2007

• Pepper, C. J. et al. 2007. Highly purified CD38+ and CD38- sub-clones derived from the same chronic lymphocytic leukemia patient have distinct gene expression signatures despite their monoclonal origin. Leukemia 21(4), pp. 687-696. (10.1038/sj.leu.2404587)

1999

• Brown, S. A., Davies, S. V., Fegan, C. D., West, R. R., Giddings, J., Whittaker, J. and Burnett, A. K. 1999. Haemostatic and fibrinolytic responses to bone marrow transplantation. British Journal of Haematology 104(3), pp. 468-474. (10.1046/j.1365-2141.1999.01223.x)

1998

• Brown, S. A. et al. 1998. Parenteral glutamine protects hepatic function during bone marrow transplantation. Bone Marrow Transplantation 22(3), pp. 281-284. (10.1038/sj.bmt.1701321)

1996

• Brown, S. A. et al. 1996. A biphasic haemostatic response during bone marrow transplantation [Abstract]. Blood 88(10), pp. 1638.

1994

• Poynton, C. H. et al. 1994. Aberrant durface phenotype in MDS confers a poor-prognosis with more rapid development of AML [Abstract]. Blood 84(10), pp. A316.

1993

• Jackson, S. K., Parton, J., Barnes, R. A., Poynton, C. H. and Fegan, C. D. 1993. Effect of IgM-enriched intravenous immunoglobulin (Pentaglobin) on endotoxaemia and anti-endotoxin antibodies in bone marrow transplantation. European Journal of Clinical Investigation 23(9), pp. 540-545. (10.1111/j.1365-2362.1993.tb00963.x)

1992

• Poynton, C. H., Jackson, S., Fegan, C. D., Barnes, R. A. and Whittaker, J. A. 1992. Use of IgM enriched intravenous immunoglobulin (Pentaglobin) in bone marrow transplantation. Bone Marrow Transplantation -Basingstoke then London- 9(6), pp. 451-457.